利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.015 秒)

    COMBINATION THERAPIES TARGETING TUMOR-ASSOCIATED STROMA OR TUMOR CELLS
    1.
    发明申请
    COMBINATION THERAPIES TARGETING TUMOR-ASSOCIATED STROMA OR TUMOR CELLS 审中-公开
    靶向肿瘤相关的STROMA或肿瘤细胞的组合治疗

    公开(公告)号：WO2015191602A3

    公开(公告)日：2016-03-24

    申请号：PCT/US2015034933

    申请日：2015-06-09

    申请人： BIOMED VALLEY DISCOVERIES INC ,  US HEALTH

    发明人： SAHA SAURABH ,  ZHANG XIAOYAN M ,  DIMITROV DIMITER ,  ZHU ZHONGYU ,  ST CROIX BRAD ,  ZUDAIRE ENRIQUE

    IPC分类号： A61K35/00 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30

    CPC分类号： A61K39/39558 ,  A61K31/192 ,  A61K31/337 ,  A61K31/415 ,  A61K31/4745 ,  A61K47/48438 ,  A61K47/48569 ,  A61K47/6817 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/22 ,  C07K16/28

    摘要： The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of an agent selected from the group consisting of an anti-angiogenic agent, a vascular disrupting agent (VDA), and combinations thereof; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody contains: (i) a heavy chain variable region (VH), which includes an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7; and (ii) a light chain variable region (VL), which includes an amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8. Compositions, including pharmaceutical compositions, and kits for treating diseases, such as cancer, are also provided.

    摘要翻译： 本发明尤其提供了在受试者中治疗或改善疾病如癌症的作用的方法。 所述方法包括：向有需要的受试者施用（a）治疗有效量的选自抗血管生成剂，血管破坏剂（VDA）及其组合的药剂; 和（b）治疗有效量的单克隆抗体或其抗原结合片段，其中所述单克隆抗体含有：（i）重链可变区（VH），其包含选自SEQ ID NO：1， SEQ ID NO：3，SEQ ID NO：5和SEQ ID NO：7; 和（ii）轻链可变区（VL），其包含选自SEQ ID NO：2，SEQ ID NO：4，SEQ ID NO：6和SEQ ID NO：8的氨基酸序列。 还提供了组合物，包括药物组合物和用于治疗疾病如癌症的试剂盒。

    COMBINATION THERAPIES TARGETING TUMOR-ASSOCIATED STROMA OR TUMOR CELLS AND MICROTUBULES
    7.
    发明申请
    COMBINATION THERAPIES TARGETING TUMOR-ASSOCIATED STROMA OR TUMOR CELLS AND MICROTUBULES 审中-公开
    靶向肿瘤相关的STROMA或肿瘤细胞和微管的组合治疗

    公开(公告)号：WO2015191590A3

    公开(公告)日：2016-03-24

    申请号：PCT/US2015034917

    申请日：2015-06-09

    申请人： BIOMED VALLEY DISCOVERIES INC ,  US HEALTH

    发明人： SAHA SAURABH ,  ZHANG XIAOYAN M ,  DIMITROV DIMITER ,  ZHU ZHONGYU ,  ST CROIX BRAD ,  ZUDAIRE ENRIQUE

    IPC分类号： A61P35/00 ,  A61K39/395 ,  C07K16/30

    CPC分类号： A61K39/39558 ,  A61K31/337 ,  A61K45/06 ,  A61K47/48384 ,  A61K47/48569 ,  A61K47/6803 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/22 ,  C07K16/28 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  A61K2300/00

    摘要： The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a microtubule inhibitor; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody contains: (i) a heavy chain variable region (VH), which includes an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7; and (ii) a light chain variable region (VL), which includes an amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8. Compositions, including pharmaceutical compositions, and kits for treating diseases, such as cancer, are also provided herein.

    摘要翻译： 本发明尤其提供了在受试者中治疗或改善疾病如癌症的作用的方法。 所述方法包括：向有需要的受试者施用（a）治疗有效量的微管抑制剂; 和（b）治疗有效量的单克隆抗体或其抗原结合片段，其中所述单克隆抗体含有：（i）重链可变区（VH），其包含选自SEQ ID NO：1的氨基酸序列， SEQ ID NO：3，SEQ ID NO：5和SEQ ID NO：7; 和（ii）轻链可变区（VL），其包含选自SEQ ID NO：2，SEQ ID NO：4，SEQ ID NO：6和SEQ ID NO：8的氨基酸序列。 本文还提供了组合物，包括药物组合物和用于治疗疾病如癌症的试剂盒。

    CARTILAGE TARGETING AGENTS AND THEIR USE
    10.
    发明申请
    CARTILAGE TARGETING AGENTS AND THEIR USE 审中-公开
    卡特彼勒代理及其使用

    公开(公告)号：WO2015108998A3

    公开(公告)日：2015-10-22

    申请号：PCT/US2015011433

    申请日：2015-01-14

    申请人： US HEALTH

    发明人： BARON JEFFREY ,  CHEUNG CRYSTAL SAO FONG ,  LUI JULIAN CHUN KIN ,  DIMITROV DIMITER ,  ZHU ZHONGYU

    IPC分类号： A61K39/395 ,  A61K39/00 ,  C07K16/18 ,  C07K16/24

    CPC分类号： C07K16/18 ,  A61K47/6811 ,  A61K47/6843 ,  A61K2039/505 ,  C07K14/78

    摘要： Monoclonal antibodies and antibody fragments that specifically bind to matrilin-3, conjugates including these molecules, and nucleic acid molecules encoding the antibodies, antigen binding fragments and conjugates, are disclosed. Also disclosed are compositions including the disclosed antibodies, antigen binding fragments, conjugates, and nucleic acid molecules. Methods of treating or inhibiting a cartilage disorder in a subject, as well as methods of increasing chondrogenesis in cartilage tissue are further provided. The methods can be used, for example, for treating or inhibiting a growth plate disorder in a subject, such as a skeletal dysplasia or short stature.

    摘要翻译： 公开了特异性结合matrilin-3，包括这些分子的缀合物和编码抗体的核酸分子，抗原结合片段和缀合物的单克隆抗体和抗体片段。 还公开了包括所公开的抗体，抗原结合片段，缀合物和核酸分子的组合物。 进一步提供了在受试者中治疗或抑制软骨病症的方法以及增加软骨组织软骨形成的方法。 所述方法可用于例如治疗或抑制受试者中的生长板障碍，例如骨骼发育不良或身材矮小。